Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Osimertinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
| ▸ | INSR | P06213 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | CCKAR | P32238 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osimertinib SCHEMBL29378405 | 1.00 | EGFR (1.00) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL29350904 | 1.00 | EGFR (1.00) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL14661152 | 0.97 | EGFR (0.95) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL29375936 | 0.97 | EGFR (0.95) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL29353024 | 0.97 | EGFR (0.95) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19336957 | 0.96 | EGFR (0.92) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL18870130 | 0.95 | EGFR (0.91) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19336988 | 0.94 | EGFR (0.89) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19254678 | 0.94 | EGFR (0.89) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19336896 | 0.94 | EGFR (0.88) | EGFRMLNRKDM1AABCB11ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 447 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017930-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291 | ASTRAZENECA AB (SE) | 2025-01-16 | — | — | US | claimed |
| US-20240425476-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2024-12-26 | — | — | US | claimed |
| US-20240189310-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291 | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | US | claimed |
| US-20240182441-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-06 | — | — | US | claimed |
| CN-110483486-B | Crystal form of oxtinib ketorolac and preparation method thereof | 鲁南制药集团股份有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-113372331-B | Novel crystal form of Orientinib monohydrate | 鲁南制药集团股份有限公司 | 2023-09-12 | — | — | CN | claimed |
| CN-113372332-B | Novel crystal form of octreotide | 鲁南制药集团股份有限公司 | 2023-09-12 | — | — | CN | claimed |
| US-20220395502-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291 | ASTRAZENECA AB (SE) | 2022-12-15 | — | — | US | claimed |
| CN-114712362-A | Pharmaceutical compositions comprising AZD9291 | 阿斯利康(瑞典)有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-105848647-B | Pharmaceutical compositions comprising AZD9291 | 阿斯利康(瑞典)有限公司 | 2022-04-26 | — | — | CN | claimed |
| US-20160324854-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291 | ASTRAZENECA AB (SE) | 2016-11-10 | — | — | US | claimed |
| EP-3089741-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291 | Astrazeneca AB (SE) | 2016-11-09 | — | — | EP | claimed |
| EP-3009431-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | Astrazeneca AB (SE) | 2016-04-20 | — | — | EP | claimed |
| EP-2736895-B1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2016-01-06 | — | — | EP | claimed |
| WO-2015195228-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| WO-2015101791-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291 | ASTRAZENECA AB (SE) | 2015-07-09 | — | — | WO | claimed |
| US-8946235-B2 | 2-(2,4,5-substituted-anilino) pyrimidine compounds | ASTRAZENECA AB (SE) | 2015-02-03 | — | — | US | claimed |
| EP-2736895-A1 | 2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | Astrazeneca AB (SE) | 2014-06-04 | — | — | EP | claimed |
| US-20130053409-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2013-02-28 | — | — | US | claimed |
| WO-2013014448-A1 | 2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2013-01-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053409-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | EGFR 1/4885MLNR 267/4885KDM1A 4718/4885 |
| US-20250017930-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291 | MAST1, PIK3CA, CSNK2A1 | EGFR 410/4885MLNR 723/4885KDM1A 515/4885 |
| US-20240189310-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291 | MAST1, PIK3CA, CSNK2A1 | EGFR 410/4885MLNR 723/4885KDM1A 515/4885 |
| US-20240425476-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | EGFR 1/4885MLNR 267/4885KDM1A 4718/4885 |
| US-20220395502-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291 | MAST1, PIK3CA, CSNK2A1 | EGFR 410/4885MLNR 723/4885KDM1A 515/4885 |
| US-20160324854-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291 | CSNK2A1, CSNK2A3, CTTN | EGFR 246/4885MLNR 234/4885KDM1A 292/4885 |
| US-20240182441-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | EGFR 1/4885MLNR 267/4885KDM1A 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.